Navigation Links
Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
Date:5/4/2012

human population studies, lower levels of apoC-III and triglycerides correlated with a lower rate of cardiovascular events. In certain populations, apoC-III mediates insulin resistance, which can make metabolic syndrome worse. 

ABOUT HYPERTRIGLYCERIDEMIA

Hypertriglyceridemia can be caused by genetic defects, diet, obesity and uncontrolled diabetes and can lead to serious health problems, including cardiovascular disease and pancreatitis.  Triglycerides are an important measure of heart health and are routinely measured along with LDL-cholesterol and HDL-cholesterol.  Triglyceride levels of less than 150 mg/dL are considered within a normal range, and the American Heart Association recommends that a triglyceride level of less than 100 mg/dL is optimal.  Triglyceride levels of greater than 500 mg/dL are considered very high and levels greater than 1,000 mg/dL are considered to be severely high.  In these patients, diet and exercise have limited therapeutic benefit.  Patients with severely high triglycerides are at a higher risk of developing pancreatitis, a painful and sometimes fatal disease that requires hospitalization and close monitoring.  Based on prevalence data, Isis estimates there are greater than 200,000 patients with severely high triglycerides in the United States and Europe despite currently available therapies.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 26 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO™, following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drug
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
2. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
3. Research Alert -- Empire Asset Management Co. Initiates Coverage on Pacira Pharmaceuticals Inc. (NASDAQ: PCRX)
4. Bioness Initiates Study of Neuromodulation System for Chronic Peripheral Nerve Pain
5. OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial
6. Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx
7. EntreMed Initiates Plans for China Office
8. American Regent Initiates Nationwide Voluntary Recall of Phenylephrine HCl Injection, USP, 1%, 5 mL Vial, Lot# 0693, Due to Visible Particles
9. Echo Therapeutics Initiates Clinical Trials of its Symphony tCGM System in Critical Care Patients
10. Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease
11. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... Valeant Pharmaceuticals International, Inc. (NYSE: ... it has filed a premerger notification under the ... the U.S. Federal Trade Commission (FTC) relating to ... About Valeant Pharmaceuticals International, Inc. ... VRX) is a multinational specialty pharmaceutical company that ...
(Date:7/14/2014)... , July 14, 2014 Synthetic ... technology partnership with global bioengineering leader DNA2.0, ... for quick-to-market products. The integration ... machine learning optimization technologies, such as ProteinGPS™ ... process of engineering proteins in the Pareto ...
(Date:7/14/2014)... 2014  Abbott (NYSE: ABT) announced today that it will ... Mylan for equity ownership of a newly formed entity ... Abbott,s developed markets pharmaceuticals business, and will ... of approximately $5.3 billion based on Mylan,s closing stock ... business generated approximately $2 billion in sales in 2013. ...
Breaking Medicine Technology:Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 2Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 3Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 4Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 5Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 2Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 3Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 2Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 3Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 4Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 5Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 6Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 7
... /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA ), ... it has filed its Annual Report on Form 20-F with ... December 31, 2010 on April 22, 2011.  The Annual Report ... The Company will provide a hard copy of ...
... The following release is being issued by law ... Feldman & Pinto: According to two new ... Medical Journal, Bayer,s birth control pills Yaz and Yasmin, ... triple the risk of serious blood clots (known as ...
Cached Medicine Technology:Sinovac Files Annual Report on Form 20-F 2
(Date:7/14/2014)... By Kathleen Doheny ... -- Losing a spouse may be linked to multiple health ... new study. For certain seniors, widowhood may even delay ... mild memory problem, losing the spouse was associated with a ... stayed married," said study researcher Dr. Bryan Woodruff. ...
(Date:7/14/2014)... Connecticut (PRWEB) July 14, 2014 ... is celebrating its Grand Opening on Monday, July ... Connecticut 06830. The celebration will last all week ... all new patients. Everyone is welcomed to attend. ... M.D. who provides physician-administered skincare, anti-aging, weight loss ...
(Date:7/14/2014)... 2014 Many people are unhappy with ... surgery to reduce a “double chin.” A new ... need to go under the knife. Jawflex is a ... muscles, therefore tightening the skin in that area and ... is used for facial exercise, double chin elimination and ...
(Date:7/14/2014)... VA (PRWEB) July 14, 2014 Since ... a local icon to the Tysons Corner skyline and ... becoming its own municipality, known simply as “Tysons”, the ... Tysons Hotel. In addition to Tysons becoming its ... located in the heart of Tysons brings an evolution ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 Kenn Renner recently ... The video is meant to describe the business on ... broker and national speaker – Kenn Renner – is internationally ... marketing, and goal setting techniques. , Investing in real estate ... Some people do it as their career, while others like ...
Breaking Medicine News(10 mins):Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 3Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 3Health News:Jawflex | Double Chin Exercise for Double Chin Reduction 2Health News:Iconic Tyson’s Corner Hotel Embraces the New “Tysons” Evolution 2Health News:Iconic Tyson’s Corner Hotel Embraces the New “Tysons” Evolution 3Health News:Iconic Tyson’s Corner Hotel Embraces the New “Tysons” Evolution 4
... SOUTH SAN FRANCISCO, Calif., May 13 Rigel Pharmaceuticals, Inc. ... Gower, the company,s chairman and chief executive officer, is scheduled ... Securities Research Conference in San Francisco on Wednesday, May 20th ... the subsequent archived recording, log on to www.rigel.com . ...
... Science Olympiad to Emphasize the Importance of Fueling Body ... you find America,s brightest young minds launching rockets, crashing ... are part of the 25th annual Science Olympiad National ... first time, the incredible edible egg, on behalf of ...
... Gastroenterologist Offers Tips for Treatment , ... San Bruno, CA (PRWEB) May ... (AGE) affect Americans each year, according to eMedicine from WebMD. ... a viral, bacterial or parasitic infection. Victims are usually hit by ...
... medical search engine will debut on 16 May 2009 at the ... , ... Budapest, Hungary (PRWEB) May 13, 2009 -- Existing ... information to consumers. WebLib CEO Endre Jofoldi notes that "the goal ...
... ( BOVESPA: AMIL3, Bloomberg: AMIL3 BZ and Reuters: AMIL3.SA ... its results for the first quarter of 2009. ... stood at 3.11 million, 9.7% up on the 1Q08 ... 4Q08.Adjusted Operating Revenues totaled R$ 1,131 million in ...
... Adding B vitamin to grain products cut congenital heart defects ... -- Since the mandatory addition of folic acid to flour, ... than a decade ago, fewer babies have been born with ... of vitamin B, has been shown to reduce neural tube ...
Cached Medicine News:Health News:America's Top Young Scientists to Receive Scholarships for Winning Eggs-Periments 2Health News:America's Top Young Scientists to Receive Scholarships for Winning Eggs-Periments 3Health News:America's Top Young Scientists to Receive Scholarships for Winning Eggs-Periments 4Health News:When Stomach Flu Strikes, Work With, Not Against, Body's Natural Defenses 2Health News:Amilpar - Revenue Increases 13.4% and Medical Loss Ratio Falls in the First Quarter 2009 2Health News:Folic Acid Reduces Infant Heart Defects 2
Sheath Introducers with guidewires....
... design, utilizing an advanced cobalt-based ... stainless steel stents. This stronger ... for unparalleled flexibility plus optimal ... Stent Systemwith thin struts that ...
... Catheter provides support to enhance the ... adverse conditions. It gives you dependable ... your destination in cardiac interventions. It ... of clinical situations and the most ...
... Xtra, and Maximum ACT introducers represent ... specialty hemostasis introducers in the world. ... hemostasis introducers for use in interventional ... angioplasty, stenting, atherectomy, temporary pacing, endomyocardial ...
Medicine Products: